The Oncology Institute (The Oncology Institute) Cash And Cash Equivalents : $36.1 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute Cash And Cash Equivalents?

The Oncology Institute's quarterly cash and cash equivalents increased from Sep. 2023 ($27.54 Mil) to Dec. 2023 ($33.49 Mil) and increased from Dec. 2023 ($33.49 Mil) to Mar. 2024 ($36.06 Mil).

The Oncology Institute's annual cash and cash equivalents declined from Dec. 2021 ($114.30 Mil) to Dec. 2022 ($14.01 Mil) but then increased from Dec. 2022 ($14.01 Mil) to Dec. 2023 ($33.49 Mil).

The Oncology Institute Cash And Cash Equivalents Historical Data

The historical data trend for The Oncology Institute's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Oncology Institute Cash And Cash Equivalents Chart

The Oncology Institute Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

2.45

6.00

114.30

14.01

33.49

The Oncology Institute Quarterly Data
	Sep18	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial														15.25	28.89	27.54	33.49	36.06

The Oncology Institute Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

The Oncology Institute (NAS:TOI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

The Oncology Institute Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

The Oncology Institute (The Oncology Institute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703

Website

https://www.theoncologyinstitute.com

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

Executives

Havencrest Healthcare Partners, L.p.	10 percent owner	5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah	officer: Chief Financial Officer, other: Principal Financial Officer	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Brad Hively	director, officer: Chief Executive Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Jeremy Castle	officer: Chief Operating Officer	1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch	director, officer: Executive Chairman	C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller	officer: Chief Operating Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich	officer: Chief Operating Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos	officer: Chief Medical Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit	officer: Chief Accounting Officer, other: Principal Accounting Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal	director	44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling	director	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala	director	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian	10 percent owner	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara	director	C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201